낭포성 섬유증 치료 시장 규모, 점유율, 동향 분석 리포트 : 약제 클래스별, 투여 경로별, 유통 채널별, 지역별, 부문 예측(2025-2030년)

Cystic Fibrosis Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Pancreatic Enzyme Supplements), By Route of Administration (Oral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

낭포성 섬유증 치료 시장의 성장과 동향

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 낭포성 섬유증 치료 시장 규모는 2025-2030년 14.2%의 CAGR로 확대하며, 2030년에는 227억 달러에 달할 것으로 추정되고 있습니다.

낭포성 섬유증(CF)의 전 세계 유병률 증가, 주요 기업의 R&D 활동, 비영리 단체의 적극적인 노력은 예측 기간 중 시장을 촉진할 것으로 예상됩니다.

CF의 유병률 증가는 대체 치료법에 대한 수요 증가를 의미하며, 이로 인해 시장이 활기를 띠고 있습니다. 이 시장에서 활동하는 주요 기업은 비영리 단체와 협력하여 새로운 치료제를 개발하기 위해 시장 개척에 주력하고 있습니다. 임상 연구 중인 약물로는 VX-445+tezacaftor+ivacaftor, PTI-428, QR-010, AZD5634, POL6014 등이 있습니다.

지역 및 국가 비영리 단체의 적극적인 노력은 성장을 가속하는 중요한 요소 중 하나입니다. 이러한 구상은 CF 환자에 대한 지원을 보장합니다. 이들 단체는 치료제의 연구개발 활동을 지원하여 환자들의 삶의 질을 향상시키는 데 도움을 주고 있습니다. 예를 들어 북미 낭포성 섬유증 컨퍼런스(North American Cystic Fibrosis Conference, NACFC)는 1986년에 설립되어 CF 전문가들에게 CF 치료와 관련된 연구개발의 진전을 공유하기 위한 협력적이고 교육적인 포럼을 제공합니다.

낭포성 섬유증 치료 시장 보고서 하이라이트

• 세계 CF 치료 시장 규모는 2024년 10억 3,000만 달러로 추정되며, 2025-2030년 사이 14.2%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.
• CF 치료제가 2024년 44.0%의 최대 매출 점유율을 차지하며 시장을 장악했습니다. 이는 CF 치료제인 올칸비의 승인과 다양한 임상시험용 약물이 파이프라인에 존재하기 때문입니다.
• 경구 투여의 성장은 투여의 용이성과 편의성으로 인해 2024년 69.0%의 가장 큰 매출 점유율을 차지하며 시장을 주도했습니다.
• 북미가 가장 큰 시장 점유율을 차지한 이유는 이 지역에 백인 인구가 많기 때문입니다. 의료 인프라 개선, 의료비 상환, 비영리 단체의 노력은 예측 기간 중 시장을 촉진할 것으로 예상됩니다.
• 주요 기업에는 AbbVie Inc., F. Hoffmann-La Roche Ltd., Gilead, Novartis AG, Vertex Pharmaceuticals Inc., AIT(Advanced Inhalation Therapies), Alaxia, Teva Pharmaceutical Industries Ltd, Merck & Co. Inc., Alcresta Therapeutics Inc., Allergan, AstraZeneca가 있습니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 낭포성 섬유증 치료 시장 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 산업 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 낭포성 섬유증 치료 시장 : 약제 클래스 비즈니스 분석

• 약제 클래스 시장 점유율, 2024년과 2030년
• 약제 클래스 부문 대시보드
• 시장 규모와 예측과 동향 분석, 약제 클래스별, 2018-2030년
• CFTR 모듈레이터
• 췌장 효소 보충제
• 점액 용해제
• 기관지 확장제

제5장 낭포성 섬유증 치료 시장 : 투여 경로 비즈니스 분석

• 투여 경로 시장 점유율, 2024년과 2030년
• 투여 경로 부문 대시보드
• 시장 규모와 예측과 동향 분석, 투여 경로별, 2018-2030년
• 경구
• 흡입

제6장 낭포성 섬유증 치료 시장 : 유통 채널 비즈니스 분석

• 유통 채널 시장 점유율, 2024년과 2030년
• 유통 채널 부문 대시보드
• 시장 규모와 예측과 동향 분석, 유통 채널별, 2018-2030년
• 병원 약국
• 소매 약국
• 온라인 약국

제7장 낭포성 섬유증 치료 시장 : 지역별, 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 덴마크
  • 스웨덴
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 참가자 개요
• 기업의 시장 현황 분석
• 기업 분류
• 전략 지도제작
• 기업 개요/상장기업
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead
  • Novartis AG
  • Vertex Pharmaceuticals Incorporated
  • AIT(Advanced Inhalation Therapies)
  • Alaxia
  • Teva Pharmaceutical Industries Ltd.
  • Merck &Co. Inc.
  • Alcresta Therapeutics, Inc.
  • AstraZeneca

KSA

영문 목차

영문목차

Cystic Fibrosis Therapeutics Market Growth & Trends:

The global cystic fibrosis therapeutics market size is estimated to reach USD 22.7 billion by 2030, expanding at a CAGR of 14.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of Cystic Fibrosis (CF) globally, research & development activities undertaken by key players, and favorable initiatives undertaken by nonprofit organizations are expected to boost the market over the forecast period.

The rising prevalence of CF indicates the rising demand for treatment alternatives, thereby uplifting the market. The key players operating in this market in collaboration with nonprofit organizations focus on the development of novel therapeutics for treatment. Some of the drugs that are under clinical studies are VX-445 + tezacaftor + ivacaftor, PTI-428, QR-010, AZD5634, and POL6014.

Favorable initiatives taken by regional and national nonprofit organizations is one of the key factors propelling growth. These initiatives ensure support to CF patients. These organizations aid in research & development activities of these therapeutics and help improve the quality of life of these patients. For instance, North American Cystic Fibrosis Conference (NACFC) was formed in 1986 to provide a collaborative and educational forum to CF professionals to share advances in R&D related to CF therapeutics.

Cystic Fibrosis Therapeutics Market Report Highlights:

• The global CF therapeutics market size was estimated at USD 10.3 billion in 2024 and is expected to grow at a CAGR of 14.2% from 2025 to 2030
• CFTR modulators dominated the market and accounted for the largest revenue share of 44.0% in 2024 owing to the approval of CFTR modulator, Orkambi and the presence of various investigational compounds under the pipeline.
• The growth of oral administration led the market and accounted for the largest revenue share of 69.0% in 2024 due to the ease of administration and convenience
• North America accounted for the largest market share owing to the presence of Caucasian descents in this region. Improved healthcare infrastructure, reimbursements, and initiatives undertaken by the nonprofit organizations is expected to propel the market over forecast period,
• The key players include AbbVie Inc., F. Hoffmann-La Roche Ltd.; Gilead, Novartis AG, Vertex Pharmaceuticals Inc., AIT (Advanced Inhalation Therapies), Alaxia, Teva Pharmaceutical Industries Ltd, Merck & Co. Inc., Alcresta Therapeutics Inc., Allergan, and AstraZeneca

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Route of Administration
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Cystic Fibrosis Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Cystic Fibrosis Therapeutics Market: Drug Class Business Analysis

• 4.1. Drug Class Market Share, 2024 & 2030
• 4.2. Drug Class Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 4.4. CFTR Modulators
  • 4.4.1. CFTR Modulators Market, 2018 - 2030 (USD Million)
• 4.5. Pancreatic Enzyme Supplements
  • 4.5.1. Pancreatic Enzyme Supplements Market, 2018 - 2030 (USD Million)
• 4.6. Mucolytics
  • 4.6.1. Mucolytics Market, 2018 - 2030 (USD Million)
• 4.7. Bronchodilators
  • 4.7.1. Bronchodilators Market, 2018 - 2030 (USD Million)

Chapter 5. Cystic Fibrosis Therapeutics Market: Route of Administration Business Analysis

• 5.1. Route of Administration Market Share, 2024 & 2030
• 5.2. Route of Administration Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 5.4. Oral
  • 5.4.1. Oral Market, 2018 - 2030 (USD Million)
• 5.5. Inhaled
  • 5.5.1. Inhaled Market, 2018 - 2030 (USD Million)

Chapter 6. Cystic Fibrosis Therapeutics Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2024 & 2030
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 6.6. Online Pharmacies
  • 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Cystic Fibrosis Therapeutics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. U.S. Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Framework
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Canada Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Framework
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. Mexico Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. UK Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Framework
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. Germany Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Framework
    • 7.5.4.3. Competitive Insights
    • 7.5.4.4. France Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Regulatory Framework
    • 7.5.5.3. Competitive Insights
    • 7.5.5.4. Italy Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Regulatory Framework
    • 7.5.6.3. Competitive Insights
    • 7.5.6.4. Spain Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Norway
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Regulatory Framework
    • 7.5.7.3. Competitive Insights
    • 7.5.7.4. Norway Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Regulatory Framework
    • 7.5.8.3. Competitive Insights
    • 7.5.8.4. Denmark Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Sweden
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Regulatory Framework
    • 7.5.9.3. Competitive Insights
    • 7.5.9.4. Sweden Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. Japan Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Framework
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. China Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Framework
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. India Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Framework
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. South Korea Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Framework
    • 7.6.6.3. Competitive Insights
    • 7.6.6.4. Australia Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Framework
    • 7.6.7.3. Competitive Insights
    • 7.6.7.4. Thailand Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Framework
    • 7.7.2.3. Competitive Insights
    • 7.7.2.4. Brazil Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Framework
    • 7.7.3.3. Competitive Insights
    • 7.7.3.4. Argentina Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Framework
    • 7.8.2.3. Competitive Insights
    • 7.8.2.4. South Africa Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Framework
    • 7.8.3.3. Competitive Insights
    • 7.8.3.4. Saudi Arabia Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Framework
    • 7.8.4.3. Competitive Insights
    • 7.8.4.4. UAE Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamic
    • 7.8.5.2. Regulatory Frameworks
    • 7.8.5.3. Competitive Insights
    • 7.8.5.4. Kuwait Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. AbbVie Inc.
    • 8.5.1.1. Company Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. F. Hoffmann-La Roche Ltd.
    • 8.5.2.1. Company Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Gilead
    • 8.5.3.1. Company Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Novartis AG
    • 8.5.4.1. Company Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Vertex Pharmaceuticals Incorporated
    • 8.5.5.1. Company Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. AIT (Advanced Inhalation Therapies)
    • 8.5.6.1. Company Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Alaxia
    • 8.5.7.1. Company Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Teva Pharmaceutical Industries Ltd.
    • 8.5.8.1. Company Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Merck & Co. Inc.
    • 8.5.9.1. Company Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Alcresta Therapeutics, Inc.
    • 8.5.10.1. Company Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. AstraZeneca
    • 8.5.11.1. Company Overview
    • 8.5.11.2. Financial Performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic Initiatives

관련자료